Literature DB >> 31775577

Engineering drug delivery systems to overcome mucosal barriers for immunotherapy and vaccination.

Jacob C McCright1, Katharina Maisel1.   

Abstract

Mucosal surfaces protect our bodies from pathogens and external irritants using a system of biological barriers. Overcoming these barriers is a significant drug delivery challenge, particularly for immunotherapies that aim to modulate the local immune response. Reaching local lymphoid tissues and draining lymph nodes (LNs) requires crossing the mucus mesh, mucosal epithelium, and either targeting M cells covering lymphoid tissues or utilizing lymphatic transport that shuttles molecules and particulates from the periphery to the LN. We first highlight the barrier properties of mucus and mucosal epithelium, and the function of the mucosal immune system. We then dive into existing drug delivery technologies that have been engineered to overcome each of these barriers. We particularly focus on novel strategies for targeting lymphoid tissues, which has been shown to enhance immunotherapies and vaccinations, via directly targeting LNs, lymphatic vessels, and M cells that transport samples of mucosal content to the lymphoid tissues.

Keywords:  Lymphatic endothelial cells; M cells; epithelium; immunoengineering; lymph node; mucus

Year:  2019        PMID: 31775577      PMCID: PMC7063868          DOI: 10.1080/21688370.2019.1695476

Source DB:  PubMed          Journal:  Tissue Barriers        ISSN: 2168-8362


  142 in total

1.  Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles.

Authors:  Eleni Maria Varypataki; Ana Luisa Silva; Christophe Barnier-Quer; Nicolas Collin; Ferry Ossendorp; Wim Jiskoot
Journal:  J Control Release       Date:  2016-02-11       Impact factor: 9.776

Review 2.  Barrier properties of mucus.

Authors:  Richard A Cone
Journal:  Adv Drug Deliv Rev       Date:  2008-12-16       Impact factor: 15.470

Review 3.  M cell targeting engineered biomaterials for effective vaccination.

Authors:  Mohammad Ariful Islam; Jannatul Firdous; Abu Zayed Md Badruddoza; Emma Reesor; Mohammad Azad; Anwarul Hasan; Michael Lim; Wuji Cao; Simon Guillemette; Chong Su Cho
Journal:  Biomaterials       Date:  2018-11-12       Impact factor: 12.479

Review 4.  Rôle of lipids in airway function.

Authors:  J G Widdicombe
Journal:  Eur J Respir Dis Suppl       Date:  1987

Review 5.  Preventing infectious disease with passive immunization.

Authors:  L Zeitlin; R A Cone; T R Moench; K J Whaley
Journal:  Microbes Infect       Date:  2000-05       Impact factor: 2.700

6.  The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.

Authors:  S Hong; M T Wilson; I Serizawa; L Wu; N Singh; O V Naidenko; T Miura; T Haba; D C Scherer; J Wei; M Kronenberg; Y Koezuka; L Van Kaer
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

7.  Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination.

Authors:  Virginie Fievez; Laurence Plapied; Anne des Rieux; Vincent Pourcelle; Hélène Freichels; Valentine Wascotte; Marie-Lyse Vanderhaeghen; Christine Jerôme; Alain Vanderplasschen; Jacqueline Marchand-Brynaert; Yves-Jacques Schneider; Véronique Préat
Journal:  Eur J Pharm Biopharm       Date:  2009-05-04       Impact factor: 5.571

Review 8.  Niches for the Long-Term Maintenance of Tissue-Resident Memory T Cells.

Authors:  Shiki Takamura
Journal:  Front Immunol       Date:  2018-05-31       Impact factor: 7.561

9.  Delivery of Nanoparticles across the Intestinal Epithelium via the Transferrin Transport Pathway.

Authors:  Jing M Yong; Julia Mantaj; Yiyi Cheng; Driton Vllasaliu
Journal:  Pharmaceutics       Date:  2019-06-26       Impact factor: 6.321

Review 10.  Potential for Tight Junction Protein-Directed Drug Development Using Claudin Binders and Angubindin-1.

Authors:  Yosuke Hashimoto; Keisuke Tachibana; Susanne M Krug; Jun Kunisawa; Michael Fromm; Masuo Kondoh
Journal:  Int J Mol Sci       Date:  2019-08-17       Impact factor: 5.923

View more
  2 in total

Review 1.  Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome.

Authors:  Makhloufi Zoulikha; Qingqing Xiao; George Frimpong Boafo; Marwa A Sallam; Zhongjian Chen; Wei He
Journal:  Acta Pharm Sin B       Date:  2021-08-12       Impact factor: 11.413

Review 2.  Targeting the Gut Mucosal Immune System Using Nanomaterials.

Authors:  Jacob McCright; Ann Ramirez; Mayowa Amosu; Arnav Sinha; Amanda Bogseth; Katharina Maisel
Journal:  Pharmaceutics       Date:  2021-10-21       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.